Table 2.
The changes in DM patients' inflammation parameters.
| Parameters | HC | Metformin (months) | Rosiglitazone (months) | |||
| 0 | 1 | 2 | 0 | 2 | ||
| WBC × 109 | 6.7 ± 0.1 | 7.3 ± 0.3b | 7.4 ± 0.4 | 7.5 ± 0.2 | 7.04 ± 0.5b | 6.8 ± 0.6 |
| PMNLs × 109 | 4.0 ± 0.1 | 4.6 ± 0.3b | 4.7 ± 0.2 | 4.9 ± 0.1 | 4.2 ± 0.4b | 4.4 ± 0.5 |
| PMNL apoptosis (%) | 4.0 ± 0.1 | 12.7 ± 3.4b | 9.5 ± 2.8a, b | 6.5 ± 1.0a | 20.4 ± 4.4b | 7.5 ± 1.9a |
| Monocytes × 109 | 0.36 ± 0.02 | 0.44 ± 0.05b | 0.40 ± 0.04b | 0.39 ± 0.04a | 0.49 ± 0.03b | 0.39 ± 0.01a |
| Fibrinogen (mg/dl) | 304.6 ± 17.6 | 440.1 ± 25.2b | 471.1 ± 28.8b | 415.9 ± 41.2a, b | 400 ± 16.6b | 332.8 ± 8.1a,b |
| Albumin (g/dl) | 4.6 ± 0.05 | 4.53 ± 0.1 | 4.74 ± 0.1 | 4.7 ± 0.04 | 4.5 ± 0.1 | 4.6 ± 0.1 |
| Transferrin (g/dl) | 273.2 ± 10.6 | 274.6 ± 8.4 | 276.7 ± 7.2 | 287.9 ± 7.7 | 264.7 ± 7.6 | 286.2 ± 8.9 |
| CRP (mg/L) | 1.5 ± 0.1 | 8.3 ± 1.6b | 6.6 ± 1.1b | 5.8 ± 1.5a, b | 4.3 ± 0.9b | 1.8 ± 0.2a,b |
a P < 0.05, treated DM patients vs. untreated DM patients;
b P < 0.05, untreated DM patients vs. HC subjects